Skip to main content
logo
NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia flag Australia · Delayed Price · Currency is AUD
0.0590
-0.0030 (-4.84%)
Aug 5, 2026, 4:10 PM AEST

ASX:NSB Financials Overview

Millions AUD. Fiscal year is Jul - Jun.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Revenue
0.32-2.214.95-0.96
Revenue Growth
---55.34%---
Gross Profit
0.2702.194.91-0.070.92
Operating Income
-3.37-2.010.16-1.17-10.5-3.26
Net Income
-3.18-1.850.32-1.07-10.44-3.18
Earnings Per Share
-0.01-0.010.00-0.01-0.07-0.02
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Cash & Investments
6.367.274.954.917.2214.16
Total Debt
------
Net Cash (Debt)
6.367.274.954.917.2214.16
Net Cash Growth
-12.50%46.66%0.86%-31.93%-49.05%330.88%
Net Cash Per Share
0.030.050.030.030.050.10

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Operating Cash Flow
-1.39-0.940.04-2.3-6.94-2.6
Capital Expenditures
---0--0-0.03
Free Cash Flow
-1.39-0.940.04-2.3-6.95-2.63
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Gross Margin
85.34%-98.90%99.07%-95.87%
Operating Margin
-1058.85%-7.02%-23.65%--340.53%
Pretax Margin
-999.47%-14.66%-21.58%--331.45%
Profit Margin
-999.47%-14.66%-21.57%--331.45%
FCF Margin
-436.90%-1.92%-46.52%--274.46%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
PE Ratio
--17.84---
P/FCF Ratio
--136.31---
PS Ratio
76.01-2.622.32-50.13